Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Innate Pharma S.A. ADR (NQ: IPHA ) 1.845 UNCHANGED Streaming Delayed Price Updated: 1:28 PM EST, Nov 7, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Innate Pharma S.A. ADR < Previous 1 2 3 4 5 6 7 8 Next > Innate Pharma Announces Its Participation to Upcoming Investor Conferences and Conference Call for First Half 2023 Business Update August 29, 2023 From Innate Pharma SA Via Business Wire Innate Pharma to Participate in Upcoming Investor Conference August 10, 2023 From Innate Pharma SA Via Business Wire First Patient Dosed in SAR’514 / IPH6401 Phase 1/2 Clinical Trial in Relapsed/Refractory Multiple Myeloma July 11, 2023 From Innate Pharma SA Via Business Wire Number of Shares and Voting Rights of Innate Pharma as of July 1, 2023 July 07, 2023 From Innate Pharma SA Via Business Wire First Patient Dosed in Phase 2 MATISSE Trial of IPH5201 in Early Stage Lung Cancer June 26, 2023 From Innate Pharma SA Via Business Wire Innate Pharma Highlights Increased Lacutamab Clinical Activity From Interim Results of Phase 2 TELLOMAK Study With Updated Olsen Criteria June 16, 2023 From Innate Pharma SA Via Business Wire Innate Pharma to Present Updated Interim Phase 2 Efficacy Results of Lacutamab in Mycosis Fungoides at the International Conference on Malignant Lymphoma June 12, 2023 From Innate Pharma SA Via Business Wire Innate Pharma Highlights Proprietary Tetra-specific ANKET® NK Cell Engager IPH6501 at the EHA 2023 Congress June 10, 2023 From Innate Pharma SA Via Business Wire Why Shares of Innate Pharma Jumped Thursday June 08, 2023 The company's collaboration agreement with Sanofi could soon pay off. Via The Motley Fool SAR’579 / IPH6101 Receives FDA Fast Track Designation in the US for the Treatment of Hematological Malignancies June 08, 2023 From Innate Pharma SA Via Business Wire Number of Shares and Voting Rights of Innate Pharma as of June 1, 2023 June 07, 2023 From Innate Pharma SA Via Business Wire Innate Pharma Highlights Phase 1/2 Dose Escalation Safety and Preliminary Efficacy of Sanofi Developed First NK Cell Engager SAR’579 / IPH6101 in R/R AML May 26, 2023 From Innate Pharma SA Via Business Wire Innate Pharma to Participate in Upcoming Investor Conferences May 23, 2023 From Innate Pharma SA Via Business Wire Outcome of Innate Pharma’s 2023 Annual General Meeting May 12, 2023 From Innate Pharma SA Via Business Wire Innate Pharma Reports First Quarter 2023 Financial Results and Business Update May 10, 2023 From Innate Pharma SA Via Business Wire Number of shares and voting rights of Innate Pharma as of May 1, 2023 May 09, 2023 From Innate Pharma SA Via Business Wire Innate Pharma Announces Conference Call and Webcast for Q1 Business Update May 03, 2023 From Innate Pharma SA Via Business Wire Innate Pharma Highlights Clinical Abstracts Selected for ASCO 2023 Annual Meeting May 03, 2023 From Innate Pharma SA Via Business Wire Innate Pharma Establishes a New At-The-Market (“ATM”) Program on Nasdaq April 26, 2023 From Innate Pharma SA Via Business Wire Innate Pharma to Participate in Upcoming Investor Conference April 21, 2023 From Innate Pharma SA Via Business Wire Tiziana Life Sciences Has Only Fully Human Anti-CD3 mAB In Clinical Studies, Could Be Poised To Improve Care For Patients With Severe Multiple Sclerosis April 19, 2023 Tiziana Life Sciences (NASDAQ: TLSA), a London-based biotechnology company, is developing a first-in-class drug, Foralumab. Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) at the... Via Benzinga Number of Shares and Voting Rights of Innate Pharma as of April 1, 2023 April 18, 2023 From Innate Pharma SA Via Business Wire Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 12, 2023 April 07, 2023 From Innate Pharma SA Via Business Wire Innate Pharma Files Its 2022 Universal Registration Document (Document d’enregistrement universel) and 2022 Annual Report on Form 20-F April 06, 2023 From Innate Pharma SA Via Business Wire 12 Health Care Stocks Moving In Monday's Pre-Market Session April 03, 2023 Via Benzinga Innate Pharma Announces Exclusive License of Antibodies to Takeda for Celiac Disease Research Program April 03, 2023 From Innate Pharma SA Via Business Wire Earnings Scheduled For March 23, 2023 March 23, 2023 Companies Reporting Before The Bell • Cognition Therapeutics (NASDAQ:CGTX) is likely to report earnings for its fourth quarter. Via Benzinga Innate Pharma Reports Full Year 2022(1) Financial Results and Business Update March 23, 2023 From Innate Pharma SA Via Business Wire Number of Shares and Voting Rights of Innate Pharma as of March 1, 2023 March 20, 2023 From Innate Pharma SA Via Business Wire Innate Pharma Announces Conference Call and Webcast for Full Year 2022 Financial Results March 16, 2023 From Innate Pharma SA Via Business Wire < Previous 1 2 3 4 5 6 7 8 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
